UCB announced positive results from BE VIVID, the first of three Phase III studies evaluating the efficacy and safety of...
UCB, announced the first presentations of data from the Phase III clinical development program of bimekizumab, its investigational IL-17A and IL-17F inhibitor, as part of a virtual session for the American Academy of Dermatology (AAD) 2020 Annual Meeting.
The AQUARIUS study shows that Tekturna/Rasilez (aliskiren), from Novartis, neither improves nor slows the progression of coronary atherosclerosis when given...
Eli Lilly and Company announced that mirikizumab (an investigational interleukin-23p19 antagonist) met the co-primary and all major secondary endpoints compared to placebo in VIVID-1, a Phase III study evaluating the safety and efficacy of mirikizumab for the treatment of adults with moderately to severely active Crohn's disease.
The ELIXA Phase IIIb study designed to assess the cardiovascular (CV) safety of Lyxumia (lixisenatide), from Sanofi, in adults with...
In the Phase III VIVID-DME and VISTA-DME trials of Eylea (VEGF Trap-Eye) from Regeneron and Bayer, for the treatment of...
Roche announced that the European Commission has granted marketing authorisation for Tecentriq SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection
Zealand Pharma A/S announced the submission of a NDA to the FDA for dasiglucagon for the prevention and treatment of low blood sugar (hypoglycemia) in pediatric patients 7 days of age or older with congenital hyperinsulinism.
In the Phase III VIVID-DME trial of Eylea (aflibercept) Injection, from Regeneron Pharmaceuticals, for the treatment of Diabetic Macular Oedema...
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced on 7 November 2013 that Bayer HealthCare has submitted an application for marketing...